This article is more than 5 years old. Information may no longer be current.

Single injection of ocriplasmin may help resolve vitreomacular adhesions

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — Ocriplasmin, which is not approved by the U.S. Food and Drug Administration for use in cases of vitreomacular adhesions, may be useful for this indication, according to a speaker reporting phase 3 results of the MIVI-TRUST trial.

The MIVI-TRUST investigated the effect of a single intravitreal injection of 125 µg (100 µL) of ocriplasmin (ThromboGenics) compared with a single 100 µL placebo injection for the pharmacological treatment of symptomatic vitreomacular adhesion.

“Pharmacologic vitreolysis with a single injection of ocriplasmin resulted in resolution in approximately 30% of patients — up to 40% with smaller zones of adhesions,” Baruch D. Kuppermann, MD, said at the Association for Research in Vision and Ophthalmology meeting here.

The primary endpoint of the study was nonsurgical resolution of vitreomacular adhesion at day 28, the study investigators said in their presentation abstract.

“Resolution of [vitreomacular traction] frequently resulted in visual improvement (mean 7.8 letters),” Dr. Kuppermann said. “Most adverse events were transient, occurring in the first 7 days of therapy.”

“The hope is that if this is approved, ocriplasmin could provide an early treatment option for patients with [vitreomacular traction]. … Many of these [patients] had good vision and would not have been good candidates for surgery,” Dr. Kuppermann said.

• Disclosure: Dr. Kuppermann has financial relationships with Alimera, Allergan, Allegro, Fovea, Genentech, Glaukos, Novagali, Novartis, Ophthotech, Pfizer, Regeneron and ThromboGenics.